ERFURT and BERLIN, Germany – November 30, 2020 – AMP German Cannabis Group Inc. (“AMP”) (CSE: XCX) (FWB: C4T, ISIN: CA00176G1028) is proud to announce the second episode of its “Round Table” series Dr. Wieland SchinnenburgTo present MdB of the FDP, who gives an up-to-date overview of the political fields of action and related challenges on the subject of medical cannabis in Germany. In addition, the participants describe their ideas about how the industry will change for companies in this area over the next 10 years.
All episodes of the “Round Table” series are on the AMP website at www.amp-eu.de/roundtable (in German with English subtitles) on which YouTube Kanal from AMP and on all common podcast platforms (in German).
„AMP Round Table“, Episode # 2: “Medical cannabis in the focus of German politics”
War medical cannabis A relevant political area even before it was legalized, it has since gained significantly in importance and relevance due to the increased public and media awareness on the political stage.
The vast majority of political parties in Germany are fundamentally in agreement that medical cannabis rightly has its place in medicine as a potential form of treatment for known diseases. However, there is also agreement that the process that has taken place since legalization has uncovered weaknesses in various areas that must be addressed politically. Topics such as the guaranteed assumption of costs by the health insurances, adjustment of the required quantities to current values, different situations at the national level as well as a secure supply of patients by pharmacies are part of the political debate.
In the second episode of AMP’s “Round Table” series, Dr. Wieland Schinnenburg, MdB, spokesman for drug and addiction policy of the Free Democratic Party (FDP) and recognized expert on medical cannabis, with Dr. Stefan Feuerstein on the political fields of action in connection with medical cannabis and the opportunities and challenges for medical cannabis companies such as AMP.
Overview of the discussion topics:
– How do the political positions of the German parties on medical cannabis differ from one another?
– Can the current supply be better managed in view of the increasing demand for medical cannabis in Germany?
– Are the current award procedures for medical cannabis conducive to competition or the industry?
– What role must the import of medical cannabis play for the security of supply of medical cannabis?
– Could an increase in the import volumes of medical cannabis improve competition in Germany and help reduce costs for health insurance companies and private patients?
– How is the role of the cannabis agency of the Federal Institute for Drugs and Medical Devices (BfArM) to be assessed?
– How will the medical cannabis industry in Germany develop over the next five to ten years?
Dr. Wieland Schinnenburg MdB, (FDP)
Dr. Schinnenburg studied dentistry from 1978 to 1984 at the Hanover Medical School and the Westphalian Wilhelms University in Münster. After the state examination, he received his doctorate in 1985 and worked as a salaried dentist from 1984 to 1987. From 1987 until his election to the German Bundestag in 2017, he ran his own practice in Oststeinbek near Hamburg.
In addition to his work as a dentist, he began studying law at the University of Hamburg in 1989, which he completed in 1999 with the first state examination. In 1996 he passed the second state examination at the Higher Regional Court of Celle. During his studies, he completed study visits and internships in Port-au-Prince (Haiti), Los Angeles (USA), Chiang Mai (Thailand), Jerusalem (Israel) and Washington, DC (USA). In 1998, Dr. Schinnenburg in addition to his dental practice, a law firm. Since 2006, Dr. Schinnenburg Specialist lawyer for medical law and mediator since 2007.
Dr. Stefan Feuerstein (AMP)
Dr. Flint acts as a Director and President from AMP and has more than three decades of experience in brokering and managing investment opportunities from home and abroad. Dr. Feuerstein acted as managing director of IIC Industrial Investment Council GmbH, which acted as an investment promotion agency for the five eastern German states, including Berlin. He was also managing director of the TLW Thuringian Agricultural Promotion Agency (Erfurt) and the Thuringian economic department.
Mr. Holger Scholze (moderator of the panel discussion)
Holger Scholze is a German TV stock market analyst, lecturer and presenter. He became known to a wide audience primarily through his over 5,000 live broadcasts as a correspondent for the nationwide German news broadcaster.tv known. Mr. Scholze has been dealing with the international financial markets for 30 years and has been assessing the current market situation for various television and radio stations on a regular basis for two decades.
about Jushi Europe, sponsor of the second Episode the „Round Table“-Reihe
Sponsor the second episode of Round Table Series is Jushi Europe SA, the European subsidiary of Jushi Holdings Inc. (CSE; JUSH, OTCMKTS: JUSHF), which is headquartered in Switzerland. The strategy of Jushi Europe aims to set up a large-scale production in Portugal for export to the European medical cannabis market. Jushi Europe ensures a geographical diversification of the portfolio of Jushi and enables entry into cannabis markets at an early stage of development through long-term investments.
About AMP German Cannabis Group
The AMP German Cannabis Group is licensed to import medical cannabis from Europe and other countries to Germany in accordance with the Good Manufacturing Practice of the European Union (“EU-GMP”). AMP takes care of the procurement, storage, transport, delivery and sale of medical cannabis products directly to pharmaceutical distributors or pharmacists, the sole point of sale for medical cannabis to German patients with a doctor’s prescription.
You can find more information at: www.amp-eu.com
Alex Blodgett, CEO & Director
Tel: +1 236-833-1602
E-mail: [email protected]
AMP social media links:
– Twitter: https://twitter.com/AMP_Cannabis
– LinkedIn: www.linkedin.com/company/ampgermancannabisgroup
– Facebook: www.facebook.com/AMPGCG
– Instagram: www.instagram.com/ampgcg
– Podcast: http://ow.ly/EqBc50BJ4xw
Media collection: www.amp-eu.com/media-kit
The CSE and its regulatory bodies (referred to as the “Regulation Services Provider” in the CSE’s Articles of Association) assume no responsibility for the adequacy or accuracy of this press release.
This press release contains forward-looking statements that are based on the company’s expectations, estimates and projections regarding the company’s business and economic environment. This also includes the business plans and milestones as well as their timing. Although the company assumes that the expectations expressed in such forward-looking statements are based on realistic assumptions, such statements are not indicative of future performance and are subject to risks and uncertainties that are difficult to control or predict. As a result, actual results could differ materially from those expressed in such forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements were made with reference to the date of this release and the company undertakes no obligation to publicly update them by incorporating new information or future events or circumstances, unless required by applicable law.
Quelle: AMP German Cannabis Group Inc.
The source language (usually English) in which the original text is published is the official, authorized and legally valid version. This translation is included for better understanding. The German version can be shortened or summarized. No responsibility or liability is assumed for the content, correctness, appropriateness or accuracy of this translation. From the perspective of the translator, the message does not constitute a buy or sell recommendation! Please note the original English message on www.sedar.com, www.sec.gov, www.asx.com.au/ or on the company website!